All In Biotech

Free tool

FAERS Monitor: Chorionic Gonadotropin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 017016 or its brand name (Chorionic Gonadotropin, Gonadotropin, Chorionic). Reports on generic versions are filed under their own applications.

Reports

1,179

Serious

748

63% of reports

Hospitalization

412

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome244
  • drug ineffective94
  • nausea74
  • off label use68
  • abdominal distension60
  • headache60
  • dyspnoea51
  • ascites50
  • vomiting44
  • abortion spontaneous41
  • pain40
  • fatigue39
  • drug exposure during pregnancy38
  • product use in unapproved indication37
  • abdominal pain36

Reports by year received

View as table
YearReports
20049
200527
200628
200745
200820
200929
201027
201153
201281
201322
201418
20159
201644
201728
201851
201988
202056
202174
2022121
2023114
202472
202580
202683

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,980 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal2442085.71850.4453,433
ascitesSignal5030.423.21,392
drug exposure during pregnancySignal3820.014.6666
abortion spontaneousSignal4118.313.5653
abdominal distensionSignal6010.38.0494
abdominal painSignal362.82.039
product use in unapproved indicationSignal372.71.937
headache601.71.317
vomiting441.71.211
nausea741.71.320
dyspnoea511.61.211
off label use681.41.17
drug ineffective941.31.06
pain401.20.91
fatigue390.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.